MIRATI THERAPEUTICS INC (MRTX)
US60468T1051 - Common Stock
Overall MRTX gets a fundamental rating of 4 out of 10. We evaluated MRTX against 569 industry peers in the Biotechnology industry. MRTX has a great financial health rating, but its profitability evaluates not so good. MRTX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year MRTX has reported negative net income.
MRTX had a negative operating cash flow in the past year.
In the past 5 years MRTX always reported negative net income.
In the past 5 years MRTX always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of MRTX (-64.25%) is worse than 64.25% of its industry peers.
MRTX's Return On Equity of -76.69% is in line compared to the rest of the industry. MRTX outperforms 50.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.25% | ||
| ROE | -76.69% | ||
| ROIC | N/A |
ROA(3y)-40.82%
ROA(5y)-42.98%
ROE(3y)-47.43%
ROE(5y)-49.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 88.50%, MRTX belongs to the top of the industry, outperforming 90.56% of the companies in the same industry.
MRTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRTX has more shares outstanding
MRTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
MRTX has an Altman-Z score of 8.55. This indicates that MRTX is financially healthy and has little risk of bankruptcy at the moment.
MRTX has a Altman-Z score of 8.55. This is amongst the best in the industry. MRTX outperforms 83.64% of its industry peers.
There is no outstanding debt for MRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.55 |
ROIC/WACCN/A
WACC10.5%
2.3 Liquidity
MRTX has a Current Ratio of 7.54. This indicates that MRTX is financially healthy and has no problem in meeting its short term obligations.
MRTX's Current ratio of 7.54 is fine compared to the rest of the industry. MRTX outperforms 67.79% of its industry peers.
A Quick Ratio of 7.39 indicates that MRTX has no problem at all paying its short term obligations.
MRTX has a Quick ratio of 7.39. This is in the better half of the industry: MRTX outperforms 67.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.54 | ||
| Quick Ratio | 7.39 |
3. Growth
3.1 Past
MRTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.74%, which is quite good.
The Revenue has grown by 223.64% in the past year. This is a very strong growth!
MRTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.01% yearly.
EPS 1Y (TTM)8.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.42%
Revenue 1Y (TTM)223.64%
Revenue growth 3Y55.01%
Revenue growth 5YN/A
Sales Q2Q%202.03%
3.2 Future
Based on estimates for the next years, MRTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.99% on average per year.
Based on estimates for the next years, MRTX will show a very strong growth in Revenue. The Revenue will grow by 126.18% on average per year.
EPS Next Y14.07%
EPS Next 2Y13.75%
EPS Next 3Y12.15%
EPS Next 5Y12.99%
Revenue Next Year406.04%
Revenue Next 2Y283.08%
Revenue Next 3Y198%
Revenue Next 5Y126.18%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MRTX. In the last year negative earnings were reported.
Also next year MRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MRTX's earnings are expected to grow with 12.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.75%
EPS Next 3Y12.15%
5. Dividend
5.1 Amount
No dividends for MRTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MIRATI THERAPEUTICS INC
NASDAQ:MRTX (1/22/2024, 8:00:02 PM)
After market: 58.99 +0.29 (+0.49%)58.7
-0.1 (-0.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.12B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.25% | ||
| ROE | -76.69% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.5% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.54 | ||
| Quick Ratio | 7.39 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)8.74%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y14.07%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)223.64%
Revenue growth 3Y55.01%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y